



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	J-Lat Full Length Cells (8.4)
Catalog Number:	9847
Lot Number:	150243
Release Category:	C
Provided:	1 ml (4.5×10^6 cells/vial), viability is 53%.
Cell Type:	Jurkat - T lymphocyte cell line
Propagation Medium:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
Freeze Medium:	FBS, 90%; DMSO, 10%.
Growth Characteristics:	No special requirements, split 1:3 at 1×10^6 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
Morphology:	Small, spherical cells in suspension. Morphology usually does not vary.
Sterility:	Negative for bacteria, mycoplasma, and fungi.
Description:	This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
Special Characteristics:	<p>Jurkat cells were infected with the packaged retroviral construct HIV-R7/E-/GFP, which is full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in place of the Nef gene.</p> <p>Full-length constructs secrete incomplete viral particles (capsids). The cells express low to undetectable levels of GFP under basal conditions. Suited to study HIV latency and reactivation.</p>

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

The clones in this series are: 6.3 (cat# 9846), 8.4 (cat# 9847), 9.2 (cat# 9848), 10.6 (cat# 9849), and 15.4 (cat# 9850).

Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF- α

Recommended Storage:

Liquid nitrogen

Contributor:

Dr. Eric Verdin.

References:

Jordan, A., Bisgrove, D., & Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-1877. doi:10.1093/emboj/cdg188 [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Clone (clone #) from Dr. Eric Verdin." Also include the reference cited above in any publication.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated

November 09, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.